Abstract
Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have